Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Slides:

Advertisements

Similar presentations

HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.

Advertisements

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

by Nadine Martel, James Lee, and Philip S. Wells

Manuel Caceres, MD, Darryl S. Weiman, MD, JD

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

ClinicalTrials.gov Identifier NCT

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Figure 4 Observational studies on multiple treatment strategies

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Prakash Harikrishnan et al. JACEP 2015;1:

Tornado diagram of one-way deterministic sensitivity analysis.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

John A. Bittl et al. JACC 2016;68:

Masashi Maeda et al. Heart Asia 2013;5:7-14

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)

Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. Flow chart of the Jakarta Cardiovascular Care Unit (CCU) Network System. There.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Giuseppe Gargiulo et al. JACC 2018;71:

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Reduction of cardiac enzyme release by ischaemic postconditioning (PostC), adjusted on the area at risk (AAR). Reduction of cardiac enzyme release by ischaemic.

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Assessment of infarct size by biomarker measurement.

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

New electrode placement ECG from a female, age 57 with acute chest pain, shows abnormal ST elevation in leads 11, 111, aVF, V5, V6: typical findings of.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

(Case 3) Acute, isolated posterior wall myocardial infarction.

Trend of complications for patients undergoing bioprosthetic mitral valve replacement (MVR) for mitral regurgitation between 2003 and Trend of complications.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Distribution of left atrial (LA) remodel.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.

Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial infarction. Cardioprotective effects of.

Presentation transcript:

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C) subacute stent t... Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) any stent thrombosis, (B) acute stent thrombosis (<24 h), and (C) subacute stent thrombosis (≥24 h to 30 days). Mohamed Farag et al. Open Heart 2015;2:e000258 ©2015 by British Cardiovascular Society